MedTrace Logo

Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever

NCT07150065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2025-09-02

No results posted yet for this study

Summary

Sample size of 360 children with typhoid fever were enrolled and randomly divided in two groups. All the children were enrolled in the trial from Pediatrics emergency. Informed consent was obtained from parents. Demographics (name, age of child, sex of the child, duration of fever, weight, season, socioeconomic status and residence) were noted. Then children were admitted and randomly divided in two groups by using lottery method. In group A, children were given oral 200 mg levofloxacin tablet. In group B, children were given oral 900-1,000 mg ciprofloxacin tablet. All children were followed-up pediatric wards for 7 days. If fever was resolved within 5 days (body temperature falls \<99oF and remain stable for at least 5 days), then efficacy was labeled. Total time required to resolve fever i.e. body temperature \<99oF in all children was also noted. All this information was recorded

Conditions

Interventions

DRUG

Levofloxacin

Oral 200 mg levofloxacin tablet

DRUG

ciprofloxacin

Oral 900-1,000 mg ciprofloxacin tablet

Sponsors & Collaborators

  • Avicenna Medical College Lahore

    lead OTHER

Principal Investigators

  • Professor Aneela Zareen, MBBS FCPS · Avicenna Medical And Dental College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2025-08-07
Completion
2025-08-07

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07150065 on ClinicalTrials.gov